We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
-18.21%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$12.2B
AUM Growth
-$2.97B
Cap. Flow
+$24.4M
Cap. Flow %
0.2%
Top 10 Hldgs %
86.1%
Holding
101
New
4
Increased
12
Reduced
21
Closed
10

Top Buys

Rank Stock Value
1
ACAD icon
Acadia Pharmaceuticals
ACAD
+$219M
2
AMRN
Amarin Corp
AMRN
+$155M
3
KOD icon
Kodiak Sciences
KOD
+$81M
4
CMTA
Clementia Pharmaceuticals Inc.
CMTA
+$22.3M
5
KRYS icon
Krystal Biotech
KRYS
+$14M

Top Sells

Rank Stock Value
1
GHDX
Genomic Health, Inc.
GHDX
+$143M
2
SAGE
Sage Therapeutics
SAGE
+$80.2M
3
NVTA
Invitae Corporation
NVTA
+$58.3M
4
ECYT
Endocyte, Inc. Common Stock
ECYT
+$45.3M
5
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$21.5M

Sector Composition

Rank Sector Weight
1 Healthcare 92.2%
2 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SGEN
1
DELISTED
Seagen Inc. Common Stock
SGEN
$2.89B 23.68%
51,046,060
– –
INCY icon
2
Incyte
INCY
$25.3B
$2.18B 17.83%
34,251,607
+298
+0% +$19.4K
ONC
3
BeOne Medicines Ltd
ONC
$33.9B
$1.68B 13.74%
11,959,824
– –
ALXN
4
DELISTED
Alexion Pharmaceuticals
ALXN
$833M 6.82%
8,555,894
– –
GHDX
5
DELISTED
Genomic Health, Inc.
GHDX
$756M 6.19%
11,744,010
-2,046,960
-15% -$143M
BMRN icon
6
BioMarin Pharmaceuticals
BMRN
$11.9B
$646M 5.29%
7,589,294
+6,210
+0.1% +$591K
ACAD icon
7
Acadia Pharmaceuticals
ACAD
$4.46B
$642M 5.26%
39,713,842
+11,274,728
+40% +$219M
AMRN
8
Amarin Corp
AMRN
$300M
$580M 4.75%
2,129,641
+426,166
+25% +$155M
ASND icon
9
Ascendis Pharma A/S
ASND
$16.5B
$178M 1.46%
2,837,352
– –
MDGL icon
10
Madrigal Pharmaceuticals
MDGL
$12.4B
$132M 1.08%
1,169,278
– –
HRTX icon
11
Heron Therapeutics
HRTX
$92.5M
$130M 1.07%
5,018,104
-7,194
-0.1% -$198K
BCRX icon
12
BioCryst Pharmaceuticals
BCRX
$2.44B
$122M 1%
15,103,081
– –
MRTX
13
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$107M 0.87%
2,513,462
– –
ARGX icon
14
argenx
ARGX
$54.9B
$97.9M 0.8%
1,019,557
– –
KNSA icon
15
Kiniksa Pharmaceuticals
KNSA
$6.11B
$84.3M 0.69%
3,000,000
– –
RYTM icon
16
Rhythm Pharmaceuticals
RYTM
$7.33B
$72.8M 0.6%
2,708,200
– –
ARRY
17
DELISTED
Array Biopharma Inc
ARRY
$71.8M 0.59%
5,041,696
-614,500
-11% -$9.32M
KOD icon
18
Kodiak Sciences
KOD
$2.44B
$64.9M 0.53%
+9,145,115
New +$81M
CERS icon
19
Cerus
CERS
$573M
$54.5M 0.45%
10,749,937
– –
ONCE
20
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$54.2M 0.44%
1,384,130
– –
NBIX icon
21
Neurocrine Biosciences
NBIX
$18.2B
$52.2M 0.43%
730,355
-214,269
-23% -$20.5M
PRNB
22
DELISTED
Principia Biopharma Inc. Common Stock
PRNB
$49M 0.4%
1,787,807
– –
CMTA
23
DELISTED
Clementia Pharmaceuticals Inc.
CMTA
$43.8M 0.36%
3,724,445
+1,790,821
+93% +$22.3M
NVTA
24
DELISTED
Invitae Corporation
NVTA
$43.2M 0.35%
3,902,421
-4,496,990
-54% -$58.3M
GWPH
25
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$41.7M 0.34%
428,345
+31,645
+8% +$4.15M
1
2 3 4

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q4 2018 Portfolio in Review

As of Q4 2018, Baker Bros. Advisors held 101 positions worth $12.2B, down 20% from $15.2B the previous quarter. Its ten largest holdings account for 86% of the portfolio.

Baker Bros. Advisors's Q4 2018 filing shows 4 new, 12 increased, 21 reduced and 10 closed positions. Its largest new stake was Kodiak Sciences: 9,145,115 shares worth $64.9M. The largest sale was Genomic Health, Inc., an estimated $143M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 91% a quarter earlier, followed by Technology.

  • Baker Bros. Advisors's largest Q4 2018 buy was Kodiak Sciences: 9,145,115 shares worth $64.9M.
  • Baker Bros. Advisors added most to Acadia Pharmaceuticals in Q4 2018, an estimated $219M increase.
  • Baker Bros. Advisors's biggest Q4 2018 reduction was Genomic Health, Inc., cutting an estimated $143M.
  • Baker Bros. Advisors fully exited Sage Therapeutics in Q4 2018, selling an estimated $80.2M.
  • Baker Bros. Advisors's ten largest holdings make up 86% of its $12.2B portfolio in Q4 2018.
  • Baker Bros. Advisors opened 4 new positions and closed 10 in Q4 2018.
  • Baker Bros. Advisors's portfolio value fell 20% quarter-over-quarter to $12.2B.

Based on Baker Bros. Advisors's 13F filing for Q4 2018, filed 13 Feb 2019.